A Seattle palliative care physician has filed a lawsuit against the DEA, contesting its decision to ban psilocybin for use by terminally ill patients.
In support of the cause, a coalition led by state attorneys general, civil rights organizations and academics have filed amicus briefs, or friends of the court, meant to provide additional expertise on the issues pertaining to the case.
This week, the suing parties filed an Opening Brief in the Ninth Circuit Court of Appeals arguing that under the state and federal Right to Try Act seriously ill patients have a right to use medicines that are currently undergoing clinical trials, such as psilocybin (the active compound in magic mushrooms) and MDMA.
Unlocking access to psychedelics through this path could bring about new possibilities for end-of-life patients to use psychedelic medicine, which is similar to how Canada is currently allowing access.
Background of the Case
The right to try act protects access to investigational drugs not yet approved for use, taking into consideration that terminally ill patients do not have the time to wait until a drug has been approved.